Myostatin-activin pathway inhibitors, initially developed for patients affected by muscle-wasting diseases such as Duchenne muscular dystrophy, show promise for therapeutic applications to preserve muscle mass while reducing fat tissue during weight loss in obesity treatment [46]. Here, MSTN is linked to Obesity.